CY1110037T1 - Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες - Google Patents

Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες

Info

Publication number
CY1110037T1
CY1110037T1 CY20101100427T CY101100427T CY1110037T1 CY 1110037 T1 CY1110037 T1 CY 1110037T1 CY 20101100427 T CY20101100427 T CY 20101100427T CY 101100427 T CY101100427 T CY 101100427T CY 1110037 T1 CY1110037 T1 CY 1110037T1
Authority
CY
Cyprus
Prior art keywords
packages
formulations
pyridyl ethers
benzimidazolyl pyridyl
compound
Prior art date
Application number
CY20101100427T
Other languages
English (en)
Inventor
Ahmad Hashash
Sean Ritchie
Kangwen Lin
Peng Shen
Augustus Okhamafe
Rampurna Gullapalli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1110037T1 publication Critical patent/CY1110037T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Παρέχονται σκευάσματα, που περιλαμβάνουν: μια ένωση του Χημικού τύπου (I), ένα φαρμακευτικώς αποδεκτό άλας αυτών, ή ένα μείγμα οποιωνδήποτε δυο ή περισσότερων εξ αυτών, και ένα συστατικό επιλεγμένο από έναν υδρόφιλο διαλύτη, έναν λιπόφιλο διαλύτη, έναν γαλακτωματοποιητή, ή ένα μείγμα οποιωνδήποτε δυο ή περισσότερων εξ αυτών, όπου η ένωση του Χημικού τύπου (I) είναι, σε μερικές εκδοχές, τα σκευάσματα είναι υγρά. Σε άλλες εκδοχές, τα σκευάσματα είναι στερεά. Επίσης παρέχονται μέθοδοι για την παρασκευή τέτοιων σκευασμάτων.
CY20101100427T 2006-07-21 2010-05-14 Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες CY1110037T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83271506P 2006-07-21 2006-07-21
EP07810647A EP2046292B1 (en) 2006-07-21 2007-07-20 Formulations for benzimidazolyl pyridyl ethers

Publications (1)

Publication Number Publication Date
CY1110037T1 true CY1110037T1 (el) 2015-01-14

Family

ID=38819293

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100427T CY1110037T1 (el) 2006-07-21 2010-05-14 Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες

Country Status (20)

Country Link
US (1) US8455662B2 (el)
EP (1) EP2046292B1 (el)
JP (1) JP2009544617A (el)
KR (1) KR20090033904A (el)
CN (1) CN101516335B (el)
AT (1) ATE459338T1 (el)
AU (1) AU2007275634B2 (el)
BR (1) BRPI0715423A2 (el)
CA (1) CA2657346A1 (el)
CY (1) CY1110037T1 (el)
DE (1) DE602007005139D1 (el)
DK (1) DK2046292T3 (el)
ES (1) ES2340631T3 (el)
HR (1) HRP20100293T1 (el)
MX (1) MX2009000770A (el)
PL (1) PL2046292T3 (el)
PT (1) PT2046292E (el)
RU (2) RU2452469C2 (el)
SI (1) SI2046292T1 (el)
WO (1) WO2008011154A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
CN101679372A (zh) * 2007-03-02 2010-03-24 诺瓦提斯公司 Raf激酶抑制剂的固体形式
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
MX340819B (es) 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
EP2588476A4 (en) 2010-06-30 2014-07-23 Verastem Inc SYNTHESIS AND USE OF KINASE INHIBITORS
CN102336740B (zh) * 2010-07-27 2013-07-24 中国科学院上海药物研究所 一类咪唑类化合物及其用途
CN103301067B (zh) * 2012-03-15 2018-09-11 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US10561627B2 (en) * 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AU728701B2 (en) 1996-05-23 2001-01-18 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6391683B1 (en) * 2000-06-21 2002-05-21 Siliconware Precision Industries Co., Ltd. Flip-chip semiconductor package structure and process for fabricating the same
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US20040131670A1 (en) * 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
SI1499311T1 (sl) * 2002-03-29 2010-03-31 Novartis Vaccines & Diagnostic Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US20050082192A1 (en) * 2002-06-17 2005-04-21 Eric Smarr End cap support for jumbo rolls of material
US7846959B2 (en) * 2004-05-07 2010-12-07 Exelixis, Inc. Raf modulators and methods of use
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US20100231394A1 (en) * 2009-03-11 2010-09-16 Bobby Eugene Finchum Carbon monoxide detection and dissipation apparatus

Also Published As

Publication number Publication date
EP2046292B1 (en) 2010-03-03
AU2007275634A1 (en) 2008-01-24
US8455662B2 (en) 2013-06-04
BRPI0715423A2 (pt) 2013-07-02
SI2046292T1 (sl) 2010-06-30
CN101516335A (zh) 2009-08-26
EP2046292A2 (en) 2009-04-15
HRP20100293T1 (hr) 2010-06-30
RU2452469C2 (ru) 2012-06-10
PL2046292T3 (pl) 2010-08-31
ES2340631T3 (es) 2010-06-07
WO2008011154A3 (en) 2008-06-26
ATE459338T1 (de) 2010-03-15
MX2009000770A (es) 2009-01-28
JP2009544617A (ja) 2009-12-17
RU2009105819A (ru) 2010-08-27
RU2012107218A (ru) 2013-09-10
DE602007005139D1 (de) 2010-04-15
PT2046292E (pt) 2010-04-26
CN101516335B (zh) 2014-01-08
WO2008011154A2 (en) 2008-01-24
KR20090033904A (ko) 2009-04-06
CA2657346A1 (en) 2008-01-24
DK2046292T3 (da) 2010-06-07
AU2007275634B2 (en) 2011-01-20
US20100040677A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
CY1110037T1 (el) Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
EA200870545A1 (ru) Новые гетероциклические соединения
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
WO2009032034A3 (en) Stabilized picoplatin dosage form
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2005112633A3 (en) Compounds and compositions for delivering active agents
TW200716202A (en) Pediatric formulation of topiramate
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
NO20090346L (no) Pyrazolderivater som inhibitorer av cytokrom P450
UA89315C2 (en) Butylbenzene phthalein intravenous emulsion
WO2008006795A3 (en) Indole compounds
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
WO2006094799A3 (en) Pyridinone derivatives against malaria
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
WO2009060952A1 (ja) 新規製剤
WO2007124700A3 (en) Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
WO2010080414A3 (en) Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents
PA8646301A1 (es) Inhibidores de la adenilato ciclasa soluble
WO2008004100A3 (en) Therapeutic compounds
WO2015164581A8 (en) Pharmaceutical formulation of an anti-guanylyl cyclase c antibody conjugate comprising histidine or a salt thereof and polysorbate 20
WO2006111853A3 (en) Stable solid dosage forms of acid labile drug